Payment overview · 2025
General Payments
$3,601.48
174 reported records · 29 companies
Healthcare provider profile · identity verified
Mark Barats, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · WEST HOLLYWOOD, CA · NPI 1720134695
Verified facts
What the public records show
CMS Open Payments records show Mark Barats, M.D. received $3,601.48 in general payments during 2025 across 174 reported records.
Amgen Inc. accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Entresto, Farxiga, Gemtesa, Ibsrela, Kerendia, Krystexxa, Leqvio, Linzess, Mounjaro, Nurtec Odt, Ozempic, Prolia, Rayaldee, Rybelsus, Trulance, Voquezna, Vraylar, Vyepti, Xifaxan, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 714 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 730 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KRYSTEXXA as an associated drug or biological on 45998 records involving 14548 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Krystexxa by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Prolia by this doctor in 2024.
Ardelyx, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBSRELA as an associated drug or biological on 59980 records involving 18215 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Ibsrela by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 730 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 498 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYEPTI as an associated drug or biological on 30327 records involving 8800 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vyepti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Entresto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LEQVIO as an associated drug or biological on 126702 records involving 33819 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Leqvio by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 454 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rayaldee by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 265 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Nurtec Odt by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 367 claims for Voquezna by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $636.51 | 17.7% | 47 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $416.62 | 11.6% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $332.89 | 9.2% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $248.97 | 6.9% | 9 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $237.42 | 6.6% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $213.61 | 5.9% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $174.73 | 4.8% | 16 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $151.93 | 4.2% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $145.32 | 4.0% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $128.65 | 3.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $113.36 | 3.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.45 | 2.8% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $89.21 | 2.5% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $72.55 | 2.0% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $57.98 | 1.6% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $55.57 | 1.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.24 | 1.5% | 2 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $52.34 | 1.4% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $45.47 | 1.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.40 | 1.2% | 2 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $32.76 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.36 | 0.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.70 | 0.9% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $27.55 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.69 | 0.6% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $22.03 | 0.6% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $21.71 | 0.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.42 | 0.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.04 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,601.48 | 174 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $416.62 | 14 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $322.93 | 14 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $257.35 | 19 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $237.42 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $236.96 | 10 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $213.61 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $193.60 | 9 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $185.56 | 19 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $174.73 | 16 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $158.57 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $158.57 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $155.30 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $151.93 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $145.32 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $113.36 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $99.45 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $95.14 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $86.35 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $72.55 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $68.97 | 3 | 2025 |
Source payment records
|
|||||
| Artisan Normalized: artisan |
Device | Boston Scientific Corporation | $57.98 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $55.57 | 2 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $52.34 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.73 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $47.84 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $45.47 | 2 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.02 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $44.19 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $43.40 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.51 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $32.76 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.36 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.70 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 714 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 164 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 130 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 340 | exact normalized | Medicare Part D |
| IBSRELA ibsrela |
2025 | Ibsrela | 2024 | 180 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KRYSTEXXA krystexxa |
2025 | Krystexxa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LEQVIO leqvio |
2025 | Leqvio | 2024 | 53 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 730 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 498 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 454 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 63 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRULANCE trulance |
2025 | Trulance | 2024 | 98 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 367 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYEPTI vyepti |
2025 | Vyepti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 17 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
714 | 90 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
730 | 81 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
280 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | KRYSTEXXA open payments reported associated product |
CMS Open Payments — General Payments 45998 supporting records · 14548 recipient NPIs · example record 1226871690 |
Krystexxa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
63 | 38 |
| Ardelyx, Inc. Exact reporting entity; no affiliate inference |
2025 | IBSRELA open payments reported associated product |
CMS Open Payments — General Payments 59980 supporting records · 18215 recipient NPIs · example record 1247828901 |
Ibsrela · 2024 Exact normalized brand match · 1 Part D row |
180 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
130 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
117 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
256 | 31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
85 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
730 | 81 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
256 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
498 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | VYEPTI open payments reported associated product |
CMS Open Payments — General Payments 30327 supporting records · 8800 recipient NPIs · example record 1251760014 |
Vyepti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
164 | 23 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | LEQVIO open payments reported associated product |
CMS Open Payments — General Payments 126702 supporting records · 33819 recipient NPIs · example record 1200004747 |
Leqvio · 2024 Exact normalized brand match · 1 Part D row |
53 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
454 | 60 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
265 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
98 | 11 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
367 | 77 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
98 | 16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
340 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diclofenac Sodium | Diclofenac Sodium | 1711 | 206 |
| Febuxostat | Febuxostat | 1683 | 201 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1649 | 194 |
| Amlodipine Besylate | Amlodipine Besylate | 1156 | 129 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 1023 | 106 |
| Repatha Sureclick | Evolocumab | 1003 | 105 |
| Icosapent Ethyl | Icosapent Ethyl | 963 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 955 | 103 |
| Lidocaine | Lidocaine | 882 | 100 |
| Dexlansoprazole Dr | Dexlansoprazole | 859 | 101 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 819 | 111 |
| Nebivolol Hcl | Nebivolol Hcl | 767 | 86 |
| Gabapentin | Gabapentin | 757 | 92 |
| Indapamide | Indapamide | 738 | 81 |
| Linzess | Linaclotide | 730 | 81 |
| Creon | Lipase/Protease/Amylase | 714 | 90 |
| Furosemide | Furosemide | 687 | 86 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 686 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 64 |
| Metformin Hcl | Metformin Hcl | 593 | 72 |
| Losartan Potassium | Losartan Potassium | 592 | 76 |
| Ropinirole Hcl | Ropinirole Hcl | 591 | 61 |
| Clonazepam | Clonazepam | 577 | 79 |
| Meclizine Hcl | Meclizine Hcl | 548 | 64 |
| Hydralazine Hcl | Hydralazine Hcl | 516 | 57 |
| Mounjaro | Tirzepatide | 498 | 62 |
| Meloxicam | Meloxicam | 489 | 61 |
| Diclofenac Epolamine | Diclofenac Epolamine | 466 | 53 |
| Ozempic | Semaglutide | 454 | 60 |
| Vascepa | Icosapent Ethyl | 454 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 424 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 403 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 398 | 46 |
| Tramadol Hcl | Tramadol Hcl | 392 | 52 |
| Memantine Hcl Er | Memantine Hcl | 390 | 39 |
| Famotidine | Famotidine | 379 | 49 |
| Voquezna | Vonoprazan Fumarate | 367 | 77 |
| Carvedilol | Carvedilol | 364 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 364 | 38 |
| Celecoxib | Celecoxib | 358 | 43 |
| Montelukast Sodium | Montelukast Sodium | 356 | 37 |
| Omeprazole | Omeprazole | 354 | 43 |
| Memantine Hcl | Memantine Hcl | 349 | 36 |
| Ibuprofen | Ibuprofen | 346 | 62 |
| Gemtesa | Vibegron | 340 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 335 | 40 |
| Potassium Chloride | Potassium Chloride | 334 | 34 |
| Torsemide | Torsemide | 334 | 44 |
| Glimepiride | Glimepiride | 331 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 330 | 47 |
| Donepezil Hcl | Donepezil Hcl | 324 | 29 |
| Allopurinol | Allopurinol | 317 | 44 |
| Atenolol | Atenolol | 310 | 30 |
| Pitavastatin Calcium | Pitavastatin Calcium | 308 | 40 |
| Ezetimibe | Ezetimibe | 307 | 31 |
| Edarbi | Azilsartan Medoxomil | 292 | 35 |
| Metformin Er Gastric | Metformin Hcl | 289 | 33 |
| Hydrocortisone | Hydrocortisone | 282 | 38 |
| Synthroid | Levothyroxine Sodium | 280 | 30 |
| Colchicine | Colchicine | 276 | 30 |
| Azithromycin | Azithromycin | 272 | 190 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 269 | 30 |
| Clobetasol Propionate | Clobetasol Propionate | 267 | 31 |
| Eliquis | Apixaban | 265 | 33 |
| Myrbetriq | Mirabegron | 264 | 42 |
| Nitroglycerin | Nitroglycerin | 262 | 42 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 262 | 43 |
| Alprazolam | Alprazolam | 257 | 38 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 257 | 23 |
| Jardiance | Empagliflozin | 256 | 31 |
| Captopril | Captopril | 255 | 30 |
| Spironolactone | Spironolactone | 251 | 33 |
| Tavaborole | Tavaborole | 251 | 35 |
| Lorazepam | Lorazepam | 250 | 33 |
| Azelastine Hcl | Azelastine Hcl | 237 | 32 |
| Mometasone Furoate | Mometasone Furoate | 234 | 28 |
| Dutasteride | Dutasteride | 229 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 220 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 207 | 36 |
| Nifedipine Er | Nifedipine | 207 | 28 |
| Rivastigmine | Rivastigmine | 206 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 204 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 202 | 35 |
| Pregabalin | Pregabalin | 202 | 25 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 200 | 30 |
| Fluocinonide | Fluocinonide | 199 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 21 |
| Lubiprostone | Lubiprostone | 188 | 19 |
| Diflorasone Diacetate | Diflorasone Diacetate | 187 | 21 |
| Telmisartan | Telmisartan | 186 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 182 | 26 |
| Ibsrela | Tenapanor Hcl | 180 | 34 |
| Xarelto | Rivaroxaban | 176 | 17 |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 175 | 22 |
| Candesartan Cilexetil | Candesartan Cilexetil | 169 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 169 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 167 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 165 | 22 |
| Entresto | Sacubitril/Valsartan | 164 | 23 |
| Benicar | Olmesartan Medoxomil | 163 | 17 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 163 | 18 |
| Fenofibrate | Fenofibrate | 160 | 19 |
| Januvia | Sitagliptin Phosphate | 159 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 158 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 157 | 16 |
| Procto-Med Hc | Hydrocortisone | 152 | 22 |
| Ryaltris | Olopatadine Hcl/Mometasone | 148 | 43 |
| Cyclosporine | Cyclosporine | 146 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 27 |
| Valsartan | Valsartan | 143 | 16 |
| Ketoconazole | Ketoconazole | 139 | 23 |
| Lactulose | Lactulose | 138 | 17 |
| Silodosin | Silodosin | 138 | 15 |
| Trazodone Hcl | Trazodone Hcl | 138 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 137 | 13 |
| Temazepam | Temazepam | 136 | 23 |
| Mirabegron Er | Mirabegron | 135 | 23 |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 134 | 13 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 134 | 17 |
| Sertraline Hcl | Sertraline Hcl | 133 | 20 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 132 | 18 |
| Farxiga | Dapagliflozin Propanediol | 130 | 18 |
| Propranolol Hcl | Propranolol Hcl | 130 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 130 | 95 |
| Tadalafil | Tadalafil | 130 | 13 |
| Neupro | Rotigotine | 126 | 16 |
| Meloxicam | Meloxicam, Submicronized | 122 | 21 |
| Midodrine Hcl | Midodrine Hcl | 121 | 14 |
| Nexium | Esomeprazole Magnesium | 117 | 13 |
| Finasteride | Finasteride | 113 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 111 | 18 |
| Triazolam | Triazolam | 111 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 111 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 110 | 20 |
| Irbesartan | Irbesartan | 109 | 11 |
| Dayvigo | Lemborexant | 108 | 18 |
| Zaleplon | Zaleplon | 107 | 17 |
| Simvastatin | Simvastatin | 106 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 105 | 20 |
| Lisinopril | Lisinopril | 104 | 17 |
| Clotrimazole | Clotrimazole | 101 | 16 |
| Dexilant | Dexlansoprazole | 101 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 13 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 99 | suppressed |
| Eszopiclone | Eszopiclone | 99 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 99 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 98 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 98 | 15 |
| Nurtec Odt | Rimegepant Sulfate | 98 | 11 |
| Trulance | Plecanatide | 98 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 97 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 97 | 11 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 95 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 92 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 90 | suppressed |
| Uloric | Febuxostat | 90 | 14 |
| Doxepin Hcl | Doxepin Hcl | 89 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 89 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 86 | 51 |
| Ranolazine Er | Ranolazine | 86 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 85 | 20 |
| Synjardy | Empagliflozin/Metformin Hcl | 85 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 84 | suppressed |
| Cilostazol | Cilostazol | 83 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 82 | 12 |
| Baclofen | Baclofen | 81 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 81 | 13 |
| Econazole Nitrate | Econazole Nitrate | 81 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 79 | suppressed |
| Aripiprazole | Aripiprazole | 79 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 77 | suppressed |
| Chlorthalidone | Chlorthalidone | 77 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 77 | suppressed |
| Metolazone | Metolazone | 76 | 12 |
| Tradjenta | Linagliptin | 74 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 73 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 73 | suppressed |
| Bystolic | Nebivolol Hcl | 72 | 11 |
| Loperamide | Loperamide Hcl | 70 | 13 |
| Metformin Hcl Er | Metformin Hcl | 70 | 11 |
| Estradiol | Estradiol | 69 | 13 |
| Zenpep | Lipase/Protease/Amylase | 69 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 68 | suppressed |
| Nystatin | Nystatin | 68 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | suppressed |
| Primidone | Primidone | 67 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 67 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 66 | suppressed |
| Livalo | Pitavastatin Calcium | 66 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 65 | 16 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 65 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 65 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 63 | suppressed |
| Prolia | Denosumab | 63 | 38 |
| Restasis | Cyclosporine | 63 | suppressed |
| Belsomra | Suvorexant | 62 | 11 |
| Methocarbamol | Methocarbamol | 62 | 13 |
| Ondansetron Odt | Ondansetron | 62 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 62 | suppressed |
| Diovan | Valsartan | 61 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 41 |
| Prednisone | Prednisone | 60 | 53 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 44 |
| Chlorzoxazone | Chlorzoxazone | 57 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 57 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 57 | suppressed |
| Acyclovir | Acyclovir | 56 | 20 |
| Clonidine Hcl | Clonidine Hcl | 56 | suppressed |
| Sucralfate | Sucralfate | 56 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 54 | 11 |
| Leqvio | Inclisiran Sodium | 53 | 36 |
| Rizatriptan | Rizatriptan Benzoate | 52 | suppressed |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Fluconazole | Fluconazole | 49 | 34 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 49 | suppressed |
| Trulicity | Dulaglutide | 49 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 49 | suppressed |
| Acetic Acid | Acetic Acid | 48 | 12 |
| Olopatadine Hcl | Olopatadine Hcl | 46 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 46 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | 12 |
| Risperidone | Risperidone | 44 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 43 | suppressed |
| Digoxin | Digoxin | 43 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 43 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 43 | suppressed |
| Ursodiol | Ursodiol | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 41 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 41 | 34 |
| Rayos | Prednisone | 41 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 41 | suppressed |
| Naproxen | Naproxen | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 37 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 36 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 36 | suppressed |
| Vraylar | Cariprazine Hcl | 36 | suppressed |
| Zileuton Er | Zileuton | 36 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Ergotamine-Caffeine | Ergotamine Tartrate/Caffeine | 34 | suppressed |
| Ibu | Ibuprofen | 34 | 12 |
| Jublia | Efinaconazole | 34 | suppressed |
| Methimazole | Methimazole | 34 | suppressed |
| Metronidazole | Metronidazole | 34 | 22 |
| Mupirocin | Mupirocin | 34 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Renvela | Sevelamer Carbonate | 33 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Mupirocin | Mupirocin Calcium | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 21 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 29 | suppressed |
| Praluent Pen | Alirocumab | 29 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 28 | suppressed |
| Repaglinide | Repaglinide | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 21 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 27 | suppressed |
| Kerendia | Finerenone | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Proctozone-Hc | Hydrocortisone | 27 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 26 | suppressed |
| Novolog | Insulin Aspart | 26 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Repatha Syringe | Evolocumab | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Armodafinil | Armodafinil | 25 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Verquvo | Vericiguat | 25 | suppressed |
| Crestor | Rosuvastatin Calcium | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 24 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Prozac | Fluoxetine Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 22 | suppressed |
| Krystexxa | Pegloticase | 21 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Dapagliflozin-Metformin Er | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Hyzaar | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Ramelteon | Ramelteon | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Quviviq | Daridorexant Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Lofena | Diclofenac Potassium | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Vyepti | Eptinezumab-Jjmr | 18 | suppressed |
| Ztlido | Lidocaine | 18 | suppressed |
| Apidra Solostar | Insulin Glulisine | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Enulose | Lactulose | 17 | suppressed |
| Eplerenone | Eplerenone | 17 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 17 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | 16 |
| Felodipine Er | Felodipine | 16 | suppressed |
| Kristalose | Lactulose | 16 | suppressed |
| Motegrity | Prucalopride Succinate | 16 | suppressed |
| Naproxen Sodium Er | Naproxen Sodium | 16 | suppressed |
| Adlarity | Donepezil Hcl | 15 | suppressed |
| Calcipotriene | Calcipotriene | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Dermacinrx Lidogel | Lidocaine Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Mercaptopurine | Mercaptopurine | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Cyclobenzaprine Hcl Er | Cyclobenzaprine Hcl | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 13 | suppressed |
| Paricalcitol | Paricalcitol | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Tirosint | Levothyroxine Sodium | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Avapro | Irbesartan | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Cialis | Tadalafil | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Flomax | Tamsulosin Hcl | 12 | suppressed |
| Fluorouracil | Fluorouracil | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Rapaflo | Silodosin | 12 | suppressed |
| Rayaldee | Calcifediol | 12 | suppressed |
| Rozerem | Ramelteon | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Vytorin | Ezetimibe/Simvastatin | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lexapro | Escitalopram Oxalate | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Mitigare | Colchicine | 11 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Singulair | Montelukast Sodium | 11 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,601.48 · 174 records | Amgen Inc. | ACCRUFER, AREXVY, Artisan, Auvelity, BREZTRI, CREON, Cologuard Collection Kit, ENTRESTO, EVENITY, FARXIGA, FFRct, FUROSCIX, GEMTESA, IBSRELA, KISUNLA, KRYSTEXXA, Kerendia, LEQVIO, LINZESS, LOREEV XR, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, RAYALDEE, REPATHA, REXULTI, Rybelsus, SHINGRIX, TARPEYO, TRULANCE, VOQUEZNA, VRAYLAR, VYEPTI, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 34 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error